03 Mar 2017
According to findings by the German Institute for Quality and Efficiency in Health Care, added benefits to the use of Palbociclib are not proven. The drug was approved for the treatment of hormone receptor-positive breast cancer patients not eligible for standard treatments.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024